EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes of Tisagenlecleucel and Consolidative Hematopoietic Cell Transplantation in Pediatric Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Jae Won Yoo, Suejung Jo, Seongkoo Kim, Jae Wook Lee, Nack-Gyun Chung, Bin Cho

Cancers · 19.11.2026 · 18 (22) · 3700

DOI: 10.3390/cancers18223700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 19.11.2026. Verfasst von Jae Won Yoo und 5 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Chimeric antigen receptor (CAR) T-cell therapy induces high remission rates in pediatric relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but the durability of remission and the role of consolidative hematopoietic cell transplantation (HCT) in heavily pretreated patients remain unresolved. We evaluated real-world outcomes of CAR T-cell therapy and the feasibility of consolidative HCT.

Methods

We retrospectively analyzed 30 children and adolescents with R/R B-ALL who received commercial tisagenlecleucel at a single center. Survival outcomes were compared according to consolidative HCT using a time-dependent Cox model to account for immortal-time bias.

Results

Of the 30 patients, 18 (60.0%) had undergone prior allogeneic HCT and 19 (63.3%) had a high disease burden. The 1-month overall response rate was 73.3%, with measurable residual disease-negative remission in 21 patients (95.5% of responders). With a median follow-up of 19.5 months, the 1-year event-free survival (EFS) and overall survival (OS) were 57.2 ± 9.6% and 55.5 ± 9.8%, respectively. One-year relapse-free survival among responders was 77.9 ± 9.9% (67.5 ± 17.2% when censored at HCT). Patients with ≥2 prior relapses had significantly inferior EFS and OS. Twelve of 22 responders (54.5%) underwent consolidative HCT, including 6 who had prior transplantations, with no subsequent relapse; however, no statistically significant survival advantage was observed, and transplanted responders had fewer prior relapses than those who were not transplanted.

Conclusions

Treatment failure occurred mainly in patients who did not achieve remission. Consolidative HCT, including second transplantation, was feasible, but its benefit remains uncertain, and which responders require consolidation remains to be defined.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Yoo, J. W., Jo, S., Kim, S., Lee, J. W., Chung, N., & Cho, B. (2026). Real-World Outcomes of Tisagenlecleucel and Consolidative Hematopoietic Cell Transplantation in Pediatric Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Cancers, 18(22), 3700. https://doi.org/10.3390/cancers18223700

Vancouver

Yoo JW, Jo S, Kim S, Lee JW, Chung N, Cho B. Real-World Outcomes of Tisagenlecleucel and Consolidative Hematopoietic Cell Transplantation in Pediatric Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Cancers. 2026;18(22):3700. doi:10.3390/cancers18223700

BibTeX
@article{Yoo2026,
  author = {Yoo, Jae Won and Jo, Suejung and Kim, Seongkoo and Lee, Jae Wook and Chung, Nack-Gyun and Cho, Bin},
  title = {Real-World Outcomes of Tisagenlecleucel and Consolidative Hematopoietic Cell Transplantation in Pediatric Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3700},
  doi = {10.3390/cancers18223700}
}
Kostenlos starten →